Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines
Abstract Introduction For patients with locally advanced estrogen receptor or progesterone receptor-positive breast cancer, neoadjuvant endocrine therapy (NET) facilitates down-staging of the tumor and increased rates of breast-conserving surgery. However, NET remains under-utilized, and there are v...
Main Authors: | Lauren I. Madigan, Phuong Dinh, J. Dinny Graham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-020-01314-6 |
Similar Items
-
Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
by: Chao Zhang, et al.
Published: (2020-08-01) -
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
by: Tomás Reinert, et al.
Published: (2020-04-01) -
Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01) -
Estrogenic compounds -endocrine disruptors
by: Munteanu Constantin, et al.
Published: (2011-11-01) -
NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)